Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years
Roche (RHHBY) has announced a major USD 50 billion investment in the United States over the next five years. The investment plan includes new R&D sites, expanded manufacturing facilities across Indiana, Pennsylvania, Massachusetts, and California, with an additional site location pending announcement.
The expansion will create over 12,000 new jobs, including 1,000 positions at Roche and 6,500 construction jobs. Key projects include: a gene therapy manufacturing facility in Pennsylvania, a 900,000 square foot manufacturing centre for weight loss medicines, a continuous glucose monitoring facility in Indiana, and a new AI-focused R&D centre in Massachusetts for cardiovascular research.
Building upon its existing presence of 25,000 employees across 24 sites in eight US states, Roche aims to strengthen its manufacturing and distribution capabilities. The company projects that once the new facilities are operational, its US medicine exports will exceed imports.
Roche (RHHBY) ha annunciato un importante investimento di 50 miliardi di dollari negli Stati Uniti nei prossimi cinque anni. Il piano di investimento prevede nuovi siti di ricerca e sviluppo, l'espansione delle strutture produttive in Indiana, Pennsylvania, Massachusetts e California, con un ulteriore sito in attesa di annuncio.
L'espansione creerà oltre 12.000 nuovi posti di lavoro, compresi 1.000 posti direttamente in Roche e 6.500 lavori nel settore delle costruzioni. I progetti principali includono: una struttura per la produzione di terapie geniche in Pennsylvania, un centro produttivo di 83.600 metri quadrati per farmaci per la perdita di peso, un impianto per il monitoraggio continuo della glicemia in Indiana e un nuovo centro R&S focalizzato sull'intelligenza artificiale in Massachusetts per la ricerca cardiovascolare.
Basandosi sulla sua presenza attuale di 25.000 dipendenti distribuiti su 24 siti in otto stati USA, Roche punta a rafforzare le capacità produttive e di distribuzione. L'azienda prevede che, una volta operative le nuove strutture, le esportazioni di medicinali dagli Stati Uniti supereranno le importazioni.
Roche (RHHBY) ha anunciado una importante inversión de 50 mil millones de dólares en Estados Unidos durante los próximos cinco años. El plan de inversión incluye nuevos centros de I+D, expansión de las instalaciones de fabricación en Indiana, Pensilvania, Massachusetts y California, con una ubicación adicional pendiente de anuncio.
La expansión generará más de 12,000 nuevos empleos, incluyendo 1,000 puestos en Roche y 6,500 empleos en construcción. Los proyectos clave incluyen: una planta de fabricación de terapias génicas en Pensilvania, un centro de fabricación de 900,000 pies cuadrados para medicamentos para la pérdida de peso, una instalación de monitoreo continuo de glucosa en Indiana y un nuevo centro de I+D enfocado en IA en Massachusetts para investigación cardiovascular.
Apoyándose en su presencia actual de 25,000 empleados en 24 sitios en ocho estados de EE.UU., Roche busca fortalecer sus capacidades de fabricación y distribución. La empresa proyecta que, una vez operativas las nuevas instalaciones, sus exportaciones de medicamentos desde EE.UU. superarán las importaciones.
로슈(RHHBY)는 향후 5년간 미국에 500억 달러 규모의 대규모 투자를 발표했습니다. 투자 계획에는 새로운 연구개발(R&D) 시설과 인디애나, 펜실베이니아, 매사추세츠, 캘리포니아 전역의 제조 시설 확장이 포함되며, 추가 부지 위치는 추후 발표될 예정입니다.
이번 확장으로 12,000개 이상의 신규 일자리가 창출되며, 이 중 1,000개는 로슈 내 직책이고 6,500개는 건설 관련 일자리입니다. 주요 프로젝트로는 펜실베이니아의 유전자 치료제 제조 시설, 체중 감량 약품을 위한 90만 평방피트 규모의 제조 센터, 인디애나의 연속 혈당 모니터링 시설, 매사추세츠의 심혈관 연구를 위한 AI 중심 연구개발 센터가 포함됩니다.
미국 8개 주 24개 사업장에 걸쳐 25,000명의 직원이 있는 기존 기반 위에, 로슈는 제조 및 유통 역량 강화를 목표로 합니다. 회사는 신규 시설 가동 후 미국 내 의약품 수출이 수입을 초과할 것으로 예상하고 있습니다.
Roche (RHHBY) a annoncé un investissement majeur de 50 milliards de dollars aux États-Unis au cours des cinq prochaines années. Le plan d'investissement comprend de nouveaux sites de recherche et développement, ainsi que l'expansion des installations de production dans l'Indiana, la Pennsylvanie, le Massachusetts et la Californie, avec un site supplémentaire dont l'annonce est à venir.
Cette expansion créera plus de 12 000 nouveaux emplois, dont 1 000 postes chez Roche et 6 500 emplois dans le secteur de la construction. Les projets clés comprennent : une usine de fabrication de thérapies géniques en Pennsylvanie, un centre de production de 83 600 mètres carrés pour des médicaments amaigrissants, une installation de surveillance continue du glucose en Indiana, et un nouveau centre de R&D axé sur l'intelligence artificielle dans le Massachusetts dédié à la recherche cardiovasculaire.
Fort de sa présence actuelle de 25 000 employés répartis sur 24 sites dans huit États américains, Roche vise à renforcer ses capacités de production et de distribution. L'entreprise prévoit qu'une fois les nouvelles installations opérationnelles, ses exportations de médicaments depuis les États-Unis dépasseront les importations.
Roche (RHHBY) hat eine bedeutende Investition von 50 Milliarden US-Dollar in den Vereinigten Staaten für die nächsten fünf Jahre angekündigt. Der Investitionsplan umfasst neue F&E-Standorte, erweiterte Produktionsanlagen in Indiana, Pennsylvania, Massachusetts und Kalifornien, wobei ein weiterer Standort noch bekannt gegeben wird.
Die Erweiterung wird über 12.000 neue Arbeitsplätze schaffen, darunter 1.000 Stellen bei Roche und 6.500 Arbeitsplätze im Baugewerbe. Zu den Schlüsselprojekten gehören: eine Produktionsstätte für Gentherapien in Pennsylvania, ein 83.600 Quadratmeter großes Produktionszentrum für Medikamente zur Gewichtsreduktion, eine Einrichtung für kontinuierliches Glukosemonitoring in Indiana sowie ein neues, auf KI ausgerichtetes F&E-Zentrum in Massachusetts für die kardiovaskuläre Forschung.
Aufbauend auf der bestehenden Präsenz von 25.000 Mitarbeitern an 24 Standorten in acht US-Bundesstaaten will Roche seine Produktions- und Vertriebskapazitäten stärken. Das Unternehmen prognostiziert, dass nach Inbetriebnahme der neuen Anlagen die US-amerikanischen Arzneimittelexporte die Importe übersteigen werden.
- Major USD 50 billion investment strengthens US market presence
- Creation of 12,000+ new jobs indicates significant expansion
- New manufacturing facilities will improve operational capacity
- Shift to net exporter status in US medicines
- Strategic expansion into high-growth areas (gene therapy, weight loss medicines, AI research)
- Substantial capital expenditure may impact short-term financial metrics
- Extended timeline (5 years) for investment returns
- Increased operational costs from multiple new facilities
- USD 50 billion commitment includes new state-of-the art research and development (R&D) sites, new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California and an additional site location to be announced soon
- Investments will create more than 12,000 new jobs: 1,000 at Roche and more than 11,000 in support of new US manufacturing capabilities
- Roche already has a significant existing US presence with more than 25,000 employees, 15 R&D centres and 13 manufacturing sites
Basel, 22 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will invest USD 50 billion into the United States of America in the next five years. These investments further strengthen Roche’s already significant US footprint with 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions, and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities.
As part of this investment, Roche will increase its existing footprint of more than 25,000 employees in 24 sites across eight US states. The investment will include:
- Expanded and upgraded US manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon and California
- A state-of-the-art gene therapy manufacturing facility in Pennsylvania
- A new 900,000 square foot manufacturing centre to support Roche’s expanding portfolio of next generation weight loss medicines (location to be announced)
- A new manufacturing facility for continuous glucose monitoring in Indiana
- A new R&D centre in Massachusetts, conducting cutting-edge artificial intelligence (AI) research and serving as hub for our new cardiovascular, renal and metabolism research and development efforts
- Significant expansion and upgrading of our existing pharmaceuticals and diagnostics R&D centres in Arizona, Indiana and California
“Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US,” said Thomas Schinecker, Roche Group CEO. “We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”
Once all new and expanded manufacturing capacity comes on-line, Roche will export more medicines from the US than it imports. Today, its diagnostics division already has an export surplus from the US to other countries.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
| Hans Trees, PhD Phone: +41 79 407 72 58 | Sileia Urech Phone: +41 79 935 81 48 |
| Nathalie Altermatt Phone: +41 79 771 05 25 | Lorena Corfas Phone: +41 79 568 24 95 |
| Simon Goldsborough Phone: +44 797 32 72 915 | Karsten Kleine Phone: +41 79 461 86 83 |
| Nina Mählitz Phone: +41 79 327 54 74 | Kirti Pandey Phone: +49 172 6367262 |
| Yvette Petillon Phone: +41 79 961 92 50 | Dr Rebekka Schnell Phone: +41 79 205 27 03 |
Roche Investor Relations
| Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com |
Investor Relations North America
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Attachment
FAQ
What is the total value of Roche's (RHHBY) planned US investment for 2025-2030?
How many jobs will Roche's (RHHBY) new US investment create?
What new manufacturing facilities is Roche (RHHBY) building in the US?
Will Roche's (RHHBY) US expansion affect its import-export balance?
